Effect of the \textit{ADRB1} 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography

Anna Banaś · Edyta Płońska · Mateusz Kurzawski · Wanda Gornik · Marek Drożdżik

Abstract

\textbf{Purpose} The aim of this study was to determine an association between the \textit{ADRB1} 1165C>G and 145A>G polymorphisms and hemodynamic response [heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure] to dobutamine during dobutamine stress echocardiography (DSE).

\textbf{Methods} The study involved 144 patients with clinical indications for DSE. The PCR–restriction fragment length polymorphism method was used to identify the \textit{ADRB1} 1165C>G and 145A>G polymorphisms.

\textbf{Results} Heart rate during DSE increased in all analyzed study groups. Patients with the \textit{ADRB1} 1165CC and 1165CG+GG polymorphisms demonstrated similar HR, including magnitude of response [change in heart rate (ΔHR 0–30): 42.1±17.5 vs. 46.1±15.5 bpm, respectively]. HR and ΔHR 0–30 were comparable in \textit{ADRB1} 145AA and 145AG subjects in the course of DSE. SBP and DBP at all stages of DSE were similar in subjects with either polymorphism and did not differentiate patients with the \textit{ADRB1} 145AA polymorphism from those with the \textit{ADRB1} 145AG polymorphism, nor those with the \textit{ADRB1} 1165CC polymorphism from those with the \textit{ADRB1} 1165CG+GG polymorphism. No differences were noted in the magnitude of response, with the increase in SBP and DBP comparable in all genotypes. Similar observations were made in patients (25/144 studied) with atropine requirements during DSE.

\textbf{Conclusion} The \textit{ADRB1} 1165C>G and 145A>G polymorphisms are not associated with the HR, SBP and DBP responses in Polish Caucasian patients requiring diagnostic dobutamine stress echocardiography.

Keywords \textit{ADRB1} · 1165C>G and 145A>G polymorphisms · Dobutamine stress echocardiography

Introduction

The regulation of cardiovascular response, i.e. heart rate (HR) and blood pressure [both systolic (SBP) and diastolic (DBP)], during physical stress is controlled by both environmental and genetic factors. With respect to the latter, data are available that demonstrate the association of several genes, such as those encoding the beta1-adrenergic receptor [1, 2], G-protein alpha subunit [3, 4] and G-protein beta3 subunit [5], with effects on the response rate as measured by HR and BP.

The beta-adrenoreceptor system plays an important role in the regulation of the human cardiovascular system. Two common polymorphisms have been identified in the beta1-adrenergic receptor gene: \textit{ADRB1} Arg389Gly (rs1801253, c.1165C>G in exon 1) and Ser49Gly (rs1801252, c.145A>G in exon 1). In vitro studies have provided evidence for their functional basis, and these polymorphisms have been implicated in the differential response to β1-agonists and antagonists in numerous studies [6–10]. However, little information has been published on the
effects of ADRB1 polymorphisms on heart function in stress situations, and the results that have been studied are contradictory, ranging from reports of a significant association to a complete lack of influence [12–14].

Dobutamine is an inotropic synthetic catecholamine commonly used as a diagnostic tool for dobutamine stress echocardiography (DSE). Due to the positive inotropic and chronotropic effects of dobutamine, DSE has become a popular diagnostic tool for the evaluation of coronary artery disease in patients unable to undergo standard exercise stress tests. However, based on clinical observations, there are interpersonal variations in the response to dobutamine or the exercise test in terms of HR (with some patients requiring atropine administration due to an inability to complete the test and achieve target HR) and BP response [11–13]. Polymorphisms in genes involved in regulating heart function may shed light on the observed diversity in heart response to dobutamine. One of the potential candidates is the ADRB1 gene.

The aim of this study was to determine an association between ADRB1 gene polymorphisms and hemodynamic response (namely, HR, SBP and the DBP) to dobutamine during DSE.

Methods

Subjects

The study cohort consisted of 144 patients of Caucasian origin (77 women, 67 men; age range 31–80 years) with a clinical indication for DSE. Of these 144 patients, 25 required atropine administration during DSE. DSE is standardly indicated for the detection of coronary artery disease in subjects who are unable to undergo standard exercise stress testing. A detailed description of the characteristics of the patients recruited for the study is presented in Table 1. The study protocol was approved by the local ethics committee (Pomeranian Medical University, Szczecin, Poland), and all study participants gave informed written consent.

Clinical assay

Dobutamine stress echocardiography was performed according to standard guidelines in which the administration of dobutamine is steadily increased over time (from 10, 20, 30 to 40 μg/kg/min at 3-min intervals) [15]. The HR (based on 12-lead electrocardiogram) and BP were measured at baseline (after a rest period), at the start of the dobutamine infusion period and at the end of each 3-min interval. In patients with atropine requirements, i.e. in subjects who were not able to reach target HR at a dobutamine dose of 30 μg/kg/min, the drug was administered in divided doses, beginning at 0.25 mg and increasing to 1.0 mg. Most patients evaluated reached target HR at a dobutamine level of 30 μg/kg/min, which was then taken for all subjects to be the end time-point for analysis. Each subject discontinued beta-blockers and/or calcium channel blockers at least five half-lives of the drug before study onset.

Genotyping

Genomic DNA was extracted from samples of peripheral blood leukocytes according to a standard protocol. Genotyping of the ADRB1 Arg389Gly (rs1801253, c.1165C>G in exon 1) and Ser49Gly (rs1801252, c.145A>G in exon 1) polymorphisms, using a PCR–restriction fragment length polymorphism (RFLP) method with BsmFI and Eco0109I restriction enzymes, respectively, was performed as described previously [16].

Statistical analysis

Based on allele frequencies, it was expected that the number of ADRB1 1165GG and 145GG homozygotes would be low. As such, it was planned a priori that in our analysis ADRB1 1165GG and 145GG homozygotes would be combined with ADRB1 1165GG and 145GG heterozygotes. Conformity of genotype distributions to the Hardy–Weinberg law was assessed using χ²-test. Categorical baseline characteristics were compared between

| Table 1 Patient characteristics |
|------------------------------|-----------------|
| Parameter                    | Patient data    |
| Age (years)                  | 59.3±8.8        |
| Sex                          |                 |
| Female                       | 65 (54.62)      |
| Male                         | 54 (45.38)      |
| Body mass index (kg/m²)      | 27.8±3.85       |
| Smoking                      | 19 (15.97)      |
| Hypertension                 | 78 (65.55)      |
| Diabetes                     | 15 (12.60)      |
| Medication                   |                 |
| Angiotensin-converting enzyme| 55 (46.22)      |
| Acetylsalicylic acid         | 72 (60.50)      |
| Beta-blockers                | 68 (57.14)      |
| Ca²⁺-blockers                | 23 (19.33)      |
| Statins                      | 68 (57.14)      |
| Diuretics                    | 28 (23.53)      |

Patient data are given as the mean ± standard deviation (SD) or as the number of patients (n) with the percentage of patient population given in parenthesis.
groups using the Fisher exact test (Statistica ver. 8.0; Statsoft Software, Warsaw, Poland). Numerical variables between groups were evaluated by the Mann–Whitney U test. A $p$ level <0.05 was considered to be statistically significant.

**Results**

The patients were stratified into two groups based on the identification of the *ADRB1* 1165C>G or 145A>G polymorphism. No significant differences between the groups were found for the parameters presented in Table 1 (general patient data), namely, age, sex, body mass index (BMI), smoking habits, coexistent cardiovascular diseases and medication. Genotype and allele distributions fit the Hardy–Weinberg equilibrium in both study groups. Taking into account the observed genotype frequencies and the standard deviation (SD), for 119 patients this study has a >80% power to detect differences in SBP, DBP and HR if they exceed 9.5, 5.8 and 6.4, respectively, for the Ser49Gly polymorphism and 10.0, 4.3 and 9.1, respectively, for the Arg389Gly polymorphism.

For differences between starting parameters and those observed after the administration of 30 μg of dobutamine, our study has a >80% power when the difference in the mean values between genotype-stratified patients would be >11.6 (ΔSBP), 4.9 (ΔDBP) and 10.4 (ΔHR) for the Ser49Gly polymorphism and 10.0, 4.3 and 9.1, respectively, for the Arg389Gly polymorphism.

Resting hemodynamics

All resting hemodynamic parameters were similar in *ADRB1* 1165C>G and 145A>G carriers. Patients with *ADRB1* 1165CC and 1165CG+GG as well as the 145AA and 145AG genotypes were characterized by comparable resting HR, SBP and DBP (Table 2).

**Table 2** Resting systolic blood pressure, diastolic blood pressure and heart rate

| *ADRB1* polymorphism | Genotype | Mean SBP (mmHg) | $p^a$ | Mean DBP (mmHg) | $p^a$ | Mean HR (bpm) | $p^a$ |
|----------------------|----------|----------------|-------|----------------|-------|--------------|-------|
| 145A>G               | AA (n=90) | 133.4±15.7     | 0.948 | 83.4±9.8       | 0.655 | 70.5±10.7    | 0.104 |
|                      | AG (n=29) | 133.6±16.4     |       | 82.8±8.4       |       | 66.9±9.8     |       |
| 1165C>G              | CC (n=67) | 132.4±15.2     | 0.516 | 83.3±9.3       | 0.719 | 69.3±10.1    | 0.800 |
|                      | GC+GG (n=52) | 134.7±16.7 |       | 83.3±9.8       |       | 70.0±11.2    |       |

All values are given as the mean ± SD

SBP, Resting systolic blood pressure, DBP, resting diastolic BP; HR, heart rate

$^a$Significance was determined using the Mann–Whitney U test

**Table 3** Heart rate and increase in heart rate (ΔHR) at consecutive stages of DSE

| Dobutamine dose (μg/kg/min)$^a$ | *ADRB1* 145A>G | $p^b$ | *ADRB1* 1165C>G | $p^b$ |
|---------------------------------|----------------|-------|----------------|-------|
|                                 | AA (n=90) | AG (n=29) | CC (n=67) | GC+GG (n=52) |
| HR 0                            | 70.5±10.7 | 66.9±9.8 | 69.3±10.1 | 70.0±11.2 |
| HR 10                           | 75.7±10.6 | 71.7±9.2 | 74.8±10.3 | 74.7±10.6 |
| HR 20                           | 92.7±17.3 | 89.3±10.5 | 92.9±19.5 | 90.5±16.2 |
| HR 30                           | 112.6±19.9 | 113.0±18.3 | 114.5±19.4 | 110.5±19.5 |
| ΔHR 0–30                        | 42.1±17.5 | 46.1±15.5 | 45.1±18.1 | 40.5±15.4 |

All values are given as the mean ± SD

DSE, Dobutamine stress echocardiography

$^a$HR 0, 10, 20, 30, Heart rate at baseline and at 10, 20, 30 μg/kg/min dobutamine, respectively; ΔHR, Change in heart rate from baseline and the end of the experiment

$^b$Significance was determined using the Mann–Whitney test U test
The SBP at all stages of DSE was similar in patients with either polymorphism and did not differentiate ADRB1\_145AA from 145AG subjects, and ADRB1\_1165CC from 1165CG+GG cases. Differences were noted in magnitude of response (Table 4).

DBP response in the course of DSE was similar in both analyzed polymorphisms of ADRB1 gene. DBP decreased during DSE at a rate comparable in all analyzed ADRB1 subgroups. A similar trend was observed for magnitude of DBP response (Table 5).

Similarly to patients not requiring atropine, subjects with atropine demands were characterized by similar HR, SBP, DBP and magnitude of hemodynamic response in all analyzed groups of ADRB1 polymorphisms (except for some isolated SBP measurements) (Table 6).

### Discussion

The aim of this study was to define the role of the ADRB1\_1165C>G and 145A>G polymorphisms in interindividual variability to dobutamine response during DSE (among patients with clinical indication for the test). The data currently available are not consistent regarding the associations of ADRB1 single nucleotide polymorphisms with hemodynamic response during stress situations, including DSE. Our results did not demonstrate a significant association between the ADRB1\_1165C>G and 145A>G polymorphisms and three parameters of hemodynamic response during DSE, i.e. HR, SBP and DBP, or with the magnitude of response of these parameters, both in patients with and without atropine requirements within the constraints of the standard DSE protocol. These observations are in keeping with the data reported by Aquilante et al. [2] who did not demonstrate any influence of the ADRB1\_1165C>G and 145A>G polymorphisms on HR, SBP and DBP, or with the magnitude of response of these parameters, both in patients without atropine requirements within the constraints of the standard DSE protocol. These observations are in keeping with the data reported by Kindermann et al. [17], who studied the effect of dobutamine administered in the DSE protocol on HR, SBP and contractility.

### Table 4 Systolic blood pressure and its increase (ΔSBP) at consecutive stages of DSE

| Dobutamine dose (μg/kg/min)\(a\) | ADRB1\_145A>G | p\(b\) | ADRB1\_1165C>G | p\(b\) |
|----------------------------------|---------------|--------|----------------|--------|
|                                  | AA (n=90)     | AG (n=29) | CC (n=67)      | GC+GG (n=52) |
| SBP 0                            | 133.4±15.7    | 133.6±16.4 | 0.948          | 132.4±15.2 | 134.7±16.7 | 0.516 |
| SBP 10                           | 138.5±16.0    | 138.2±16.9 | 0.988          | 137.7±16.2 | 139.3±16.3 | 0.679 |
| SBP 20                           | 146.7±19.4    | 147.6±21.7 | 0.861          | 146.2±20.0 | 147.8±19.9 | 0.796 |
| SBP 30                           | 150.5±20.2    | 150.9±27.2 | 0.948          | 149.6±22.2 | 151.9±21.9 | 0.530 |
| ΔSBP 0-30                        | 17.1±16.9     | 17.3±25.1 | 0.719          | 17.1±20.6 | 17.2±17.2 | 0.755 |

All values are given as the mean ± SD

\(a\) SBP, 10, 20, 30, Systolic blood pressure at baseline and at 10, 20 and 30 μg/kg/min dobutamine, respectively; ΔSBP 0-30, change in systolic blood pressure from baseline to end of experiment

\(b\) Significance was determined using the Mann–Whitney test U test

### Table 5 Diastolic blood pressure and its increase (ΔDBP) at consecutive stages of DSE

| Dobutamine dose (μg/kg/min)\(a\) | ADRB1\_145A>G | p\(b\) | ADRB1\_1165C>G | p\(b\) |
|----------------------------------|---------------|--------|----------------|--------|
|                                  | AA (n=90)     | AG (n=29) | CC (n=67)      | GC+GG (n=52) |
| DBP 0                            | 83.4±9.8      | 82.8±8.4 | 0.655          | 83.3±9.3 | 83.3±9.8 | 0.719 |
| DBP 10                           | 87.6±10.5     | 85.3±13.7 | 0.181          | 87.0±11.6 | 86.2±11.3 | 0.900 |
| DBP 20                           | 84.0±9.5      | 82.7±9.5 | 0.319          | 83.3±10.4 | 84.3±8.1 | 0.573 |
| DBP 30                           | 80.8±9.0      | 79.9±11.2 | 0.719          | 80.1±10.6 | 81.3±8.1 | 0.443 |
| ΔDBP 0-30                        | −2.6±7.9      | −2.9±8.9 | 0.890          | −3.2±7.9 | −1.9±8.4 | 0.664 |

All values are given as the mean ± SD

\(a\) DBP 10, 20, 30, Diastolic blood pressure at baseline and at 10, 20 and 30 μg/kg/min dobutamine, respectively; ΔDBP 0-30, change in Diastolic blood pressure from baseline to end of experiment

\(b\) Significance was determined using the Mann–Whitney test U test

### Table 5 Diastolic blood pressure and its increase (ΔDBP) at consecutive stages of DSE

| Dobutamine dose (μg/kg/min)\(a\) | ADRB1\_145A>G | p\(b\) | ADRB1\_1165C>G | p\(b\) |
|----------------------------------|---------------|--------|----------------|--------|
|                                  | AA (n=90)     | AG (n=29) | CC (n=67)      | GC+GG (n=52) |
| DBP 0                            | 83.4±9.8      | 82.8±8.4 | 0.655          | 83.3±9.3 | 83.3±9.8 | 0.719 |
| DBP 10                           | 87.6±10.5     | 85.3±13.7 | 0.181          | 87.0±11.6 | 86.2±11.3 | 0.900 |
| DBP 20                           | 84.0±9.5      | 82.7±9.5 | 0.319          | 83.3±10.4 | 84.3±8.1 | 0.573 |
| DBP 30                           | 80.8±9.0      | 79.9±11.2 | 0.719          | 80.1±10.6 | 81.3±8.1 | 0.443 |
| ΔDBP 0-30                        | −2.6±7.9      | −2.9±8.9 | 0.890          | −3.2±7.9 | −1.9±8.4 | 0.664 |

All values are given as the mean ± SD

\(a\) DBP 10, 20, 30, Diastolic blood pressure at baseline and at 10, 20 and 30 μg/kg/min dobutamine, respectively; ΔDBP 0-30, change in Diastolic blood pressure from baseline to end of experiment

\(b\) Significance was determined using the Mann–Whitney test U test
parameters. These authors did not note any association between the ADRB1 1165C>G and 145A>G polymorphisms and HR and SBP, although the ADRB1 1165C>G polymorphism was associated with other hemodynamic parameters (systemic vascular resistance, ventricular endsystolic meridional wall stress). The ADRB1 145A>G polymorphism had no effect on any of the measured parameters. The findings of our study and those of Aquilante et al. [2] and Kindermann et al. [17] are in contrast to data on a German population presented by La Rosee et al. [14]. These authors evaluated the influence of the ADRB1 1165C>G polymorphism on hemodynamic response in healthy volunteers premedicated with atropine in order to block the parasympathetic system. They found a significant association between the ADRB1 polymorphism and SBP, with ADRB1 1165CC homozygotes having a greater increase in the SBP response to dobutamine during DSE than carriers of the 1165GG polymorphism. The differences between our findings and those of Aquilante et al. [2] and La Rosee et al. [14] may possibly be attributed to

| Dobutamine dose (μg/kg/min) | ADRB1 145A>G | p | ADRB1 1165C>G | p² |
|----------------------------|--------------|---|--------------|----|
|                            | AA (n=17) | AG+GG (n=8) | CC (n=16) | GC+GG (n=9) |
| 0                          | 69.1±11.9 | 65.3 ±10.0 | 68.4±12.1 | 67.0±10.2 | 0.760 |
| 10                         | 71.5±12.0 | 72.6 ±12.7 | 74.3±12.9 | 67.7±9.3  | 0.419 |
| 20                         | 76.6±15.4 | 82.5 ±11.7 | 82.7±15.7 | 71.0±7.7  | 0.074 |
| 30                         | 108.6±23.4 | 117.3±22.4 | 117.1±21.5 | 101.1±23.1 | 0.108 |
| ΔHR 0-30                   | 39.5±23.7 | 52.0 ±23.2 | 48.8±23.6 | 34.1±22.4 | 0.121 |
| SBP 0                      | 79.1±8.1 | 79.6±11.5 | 122.4±14.0 | 130.4±17.3 | 0.276 |
| SBP 10                     | 79.4±8.4 | 76.4±12.9 | 123.7±16.8 | 135.8±11.8 | 0.049 |
| SBP 20                     | 76.9±10.6 | 76.1±13.1 | 131.9±15.7 | 129.6±16.3 | 1.000 |
| SBP 30                     | 80.6±10.1 | 81.0±10.2 | 142.0±17.7 | 135.0±15.6 | 0.388 |
| ΔSBP 0-30                  | 13.4±17.4 | 15.9 ±18.7 | 19.6±16.5 | 4.6±15.6  | 0.043 |
| DBP 0                      | 79.1±8.1 | 79.6±11.5 | 78.1±10.1 | 81.2±6.9  | 0.419 |
| DBP 10                     | 79.4±8.4 | 76.4±12.9 | 76.9±10.7 | 81.1±8.0  | 0.251 |
| DBP 20                     | 76.9±10.6 | 76.1±13.1 | 76.9±12.0 | 76.1±10.1 | 0.677 |
| DBP 30                     | 80.6±10.1 | 81.0±10.2 | 79.5±11.0 | 82.9±7.6  | 0.452 |
| ΔDBP 0-30                  | 1.5±8.7 | 1.4±15.4 | 1.4±12.1 | 1.7±9.0  | 0.846 |

All values are given as the mean ± SD

²Significance was determined using the Mann–Whitney test U test

| ADRB1 polymorphisms | Type of subjects | Number of subjects | Type of stress | Results | Reference |
|---------------------|------------------|--------------------|----------------|---------|----------|
| 1165C>G 145A>G      | Patients with indications for DSE | 163 (132 Caucasians; 26 Blacks; 7 others) | DSE | No association between the polymorphisms and HR, SBP, DBP and magnitude of response | [2] |
| 1165C>G             | Healthy male volunteers premedicated with atropine | 30 Caucasians | DSE | Association between the polymorphism and SBP | [14] |
| 1165C>G 145A>G      | Patients with indications for exercise test | 890 Caucasians | Exercise test | Association between ADRB1 1165C>G maximal SBP during exercise and SBP changes from rest to maximal | [13] |
| 1165C>G 145A>G      | Healthy male volunteers | 38 Caucasians | DSE | No association between the polymorphisms and HR, SBP | [17] |
| 1165C>G 145A>G      | Patients with indications for DSE | 144 Caucasians | DSE | No association between the polymorphisms and HR, SBP, DBP and magnitude of response | Present study |
the different populations studied: those in our study and that of Aquilante et al. [2] were recruited among patients with a clinical indication for DSE, while La Rosee et al. analyzed healthy volunteers [14]. However, the negative results reported by Kindermann et al. [17] were also from a healthy population. Another factor which should be considered is the parasympathetic system blockade introduced by La Rosee et al. [14] with atropine administration; this might attenuate the genotype-related response to dobutamine in our patients and those of Aquillante et al. [2]. La Rosee et al. administered atropine to healthy volunteers prior to the study and observed effects of the ADRB1 polymorphism under cholinergic blockade, whereas the patients from our study requiring atropine to complete the DSE were not stratified according ADRB1 polymorphisms. HR was also not associated with the ADRB1 1165C>G and 145A>G polymorphisms in Finnish study conducted in patients subjected to an exercise test based on clinical indication. In this latter study, an association was noted between ADRB1 1165C>G maximal SBP during exercise and SBP changes from rest to maximal [13]. A summary of studies conducted on the association of hemodynamic changes during stress with the ADRB1 polymorphisms is presented in Table 7.

The parameter which was not affected by the ADRB1 1165C>G polymorphism in the three studies cited above was HR during DSE. All studies provided evidence that the ADRB1 polymorphism is not associated with HR response during DSE.

In summary, the ADRB1 1165C>G and 145A>G polymorphisms are not associated with the HR, SBP and DBP response in Polish Caucasian patients undergoing diagnostic dobutamine stress echocardiography.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**References**

1. Humma LM, Puckett BJ, Richardson HE et al (2001) Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol 88:1034–1037

2. Aquilante CL, Yarandi HN, Cavallari LH et al (2008) Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. Pharmacogenomics J 8:408–415

3. Jia H, Hingorani AD, Sharma P et al (1999) Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 34:8–14

4. Mao YM, Liu ZQ, Chen BL et al (2009) Effect of 393 T>C polymorphism of GNAS1 gene on dobutamine response in Chinese healthy subjects. J Clin Pharmacol 49:929–936

5. Shioji K, Kokubo Y, Mannami T et al (2004) Association between hypertension and the alpha-adducin, beta1-adrenoceptor, and G-protein beta3 subunit genes in the Japanese population; the Suita study. Hypertens Res 27:31–37

6. Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta(1)-adrenergic receptor. J Biol Chem 274:12670–12674

7. Rathz DA, Brown KM, Kramer LA, Liggett SB (2002) Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39:155–160

8. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF (2003) Beta1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74:44–52

9. Liu J, Liu ZQ, Tan ZR et al (2003) Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 74:372–379

10. Mialet Perez J, Rathz DA, Petrashevskaya NN et al (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300–1305

11. Daly AL, Linares OA, Smith MJ, Starling MR, Supiano MA (1997) Dobutamine pharmacokinetics during dobutamine stress echocardiography. Am J Cardiol 79:1381–1386

12. Aquilante CL, Humma LM, Yarandi HN et al (2004) Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography. Am J Cardiol 94:535–538

13. Nieminen T, Lehtimäki T, Laiho J et al (2006) Effects of polymorphisms in beta1-adrenoceptor and alpha-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish cardiovascular study. J Appl Physiol 100:507–511

14. La Rosée K, Hunteburth M, Rosenkrantz S, Böh m M, Schnabel P (2004) The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics 14:711–716

15. Lewandowski TJ, Armstrong WF, Bach DS (1998) Reduced test time by early identification of patients requiring atropine during dobutamine stress echocardiography. J Am Soc Echocardiogr 11:236–242

16. Rydén M, Hoffstedt J, Eriksson P, Bringman S, Aner P (2001) The Arg 389 Gly beta1-adrenergic receptor gene polymorphism and human fat cell lipolysis. Int J Obes Relat Metab Disord 25:1599–1603

17. Kindermann M, Seeland U, Ruhnke P et al (2010) Functional effects of beta(1)-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without beta-blocker administration. Clin Res Cardiol doi:10.1007/s00392-010-0221-z